You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
|
|---|---|
| Published in |
Lancet Oncology, July 2014
|
| DOI | 10.1016/s1470-2045(14)70302-x |
| Pubmed ID | |
| Authors |
Robert Coleman, David Cameron, David Dodwell, Richard Bell, Caroline Wilson, Emma Rathbone, Maccon Keane, Miguel Gil, Roger Burkinshaw, Robert Grieve, Peter Barrett-Lee, Diana Ritchie, Victoria Liversedge, Samantha Hinsley, Helen Marshall, on behalf of the AZURE investigators |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 21% |
| Belgium | 2 | 14% |
| Hungary | 1 | 7% |
| India | 1 | 7% |
| Switzerland | 1 | 7% |
| Netherlands | 1 | 7% |
| France | 1 | 7% |
| Unknown | 4 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 64% |
| Scientists | 2 | 14% |
| Practitioners (doctors, other healthcare professionals) | 2 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 274 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 1% |
| Canada | 1 | <1% |
| Mexico | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 267 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 36 | 13% |
| Student > Master | 33 | 12% |
| Student > Bachelor | 32 | 12% |
| Researcher | 26 | 9% |
| Other | 26 | 9% |
| Other | 50 | 18% |
| Unknown | 71 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 101 | 37% |
| Biochemistry, Genetics and Molecular Biology | 27 | 10% |
| Agricultural and Biological Sciences | 21 | 8% |
| Nursing and Health Professions | 12 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 2% |
| Other | 22 | 8% |
| Unknown | 85 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2023.
All research outputs
#1,096,835
of 25,954,278 outputs
Outputs from Lancet Oncology
#1,296
of 6,973 outputs
Outputs of similar age
#10,437
of 243,004 outputs
Outputs of similar age from Lancet Oncology
#15
of 139 outputs
Altmetric has tracked 25,954,278 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,973 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,004 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.